The quarter in brief
Johnson & Johnson reported third-quarter 2026 results on October 13. Sales grew 5.9% to $25.4 billion, with operational growth of 6.0% and adjusted operational growth of 6.1%Highlights. GAAP EPS was $0.09, which reflects a one-time charge for the proposed talc litigation resolution and the costs of the Firefly Bio acquisition and the Sail Biomedicines collaboration; adjusted EPS of $2.59 also reflects those dealsHighlights. Adjusted EPS compares with $2.80 a year earlier, a 7.5% declineResults.
Against expectations, the quarter was a small beat. The LSEG consensus compiled by Reuters had been $2.54 of adjusted EPS on sales of $25.28 billionReuters.
The two segments told different stories. Innovative Medicine sales were $16,757 million, up 7.9% operationallySegments, even though Stelara alone cost about 690 basis points of growthCommentary. Stelara fell 54%, reflecting biosimilar competition and the shift to newer drug classesCall. The growth drivers more than covered it: Tremfya sales of $2,396 million rose 68%Schedules, Darzalex reached $4,239 million, up 15.6% operationallySchedules, and Carvykti grew 35% to $710 millionSchedules.
MedTech sales were $8,642 million, up 2.5%Segments, and international MedTech sales were essentially flat, up 0.1%Schedules. Management did not soften it: the head of MedTech said performance was "below the standard we have set internally and below the expectations we previously communicated to investors"Call, citing increased disruption to ordering patterns, tender timing and hospital spending across more countriesCall.
What changed in the thesis
Talc is close to resolved. J&J's July proposal for the ovarian talc claims calls for a $5.5 billion commitment, with a first payment of no more than $3 billionTalc. The charge is in the third-quarter GAAP results, the agreement requires participation of at least 95% of remaining ovarian claims, and the CFO said the company is "trending to meet the 95% threshold"Call. If it closes, the largest legal overhang on the shares becomes a known, financed cost.
Guidance edged up, after a deal-driven cut. The company raised 2026 guidance to estimated reported sales of $101.2 billion and adjusted EPS of $11.10 at the midpoint, up $0.06Highlights. That follows the July 29 update, which cut adjusted EPS by about $0.64 for the Firefly and Sail transactions8-K. Excluding that dilution, EPS growth would approach 9%, and the two deals are expected to dilute 2027 adjusted EPS by $1.36 per shareCall.
Margins are under pressure. Innovative Medicine's margin fell from 44.3% to 35.4%, mainly because of about $1 billion of acquired in-process R&D for Firefly Bio, Sail transaction costs and unfavorable mix; MedTech's margin rose from 21% to 22.9% on tariff recoveriesCall. R&D spending was about $4.7 billion, or 18.3% of sales, including $1 billion for FireflyCall.
Cash generation is intact. J&J generated more than $6 billion of free cash flow in the quarter and still expects about $21 billion for the yearCall, and ended the quarter with about $28 billion of net debtCall. The fourth-quarter dividend was declared at $1.34 per shareDividend.
Bull and bear
Tremfya, Darzalex, Carvykti and the newer oncology launches keep Innovative Medicine growing high single digits as Stelara fades to a small base. Talc settles at 95% participation, MedTech recovers outside the U.S., and the planned orthopaedics separation focuses the company on faster-growing businesses. Earnings growth re-accelerates in 2028 and the shares re-rate toward about $288 (our scenario: 22x the $13.07 pre-dilution 2027 figure).
MedTech stays weak internationally, the talc deal misses its participation threshold, and U.S. pricing pressure grows. With 2027 earnings absorbing $1.36 of deal dilution, reported growth looks flat for two years, and the shares drift toward about $234 (our scenario: 20x the $11.71 consensus 2027 EPS).
The pharmaceutical franchise is the best part of the story, and it is strong. The question for a 12-month call is what the market already pays for it. With 2026 EPS growth guided at about 3% and 2027 carrying a large, known dilution, the next year of reported numbers will look modest even if the pipeline delivers.
Talc participation confirmed at 95% or more, plus a quarter of MedTech growth back above 4%, would make us bullish. A failed settlement or another MedTech shortfall would make us bearish.
Valuation
The 2026 adjusted EPS guide is $11.05 to $11.15Guidance, and analysts polled by S&P Global, as listed by StockAnalysis.com, expect $11.71 for 2027EPS Next Year. At recent prices that is about 22x next year's estimate.
| Measure | Figure | Basis |
|---|---|---|
| 2026 adjusted EPS | $11.05–$11.15 | company guidance |
| 2027 consensus EPS | $11.71 | S&P Global via StockAnalysis.com |
| 2027 deal dilution | $1.36 | company, Firefly Bio and Sail |
| 2027 EPS before dilution | ≈ $13.07 | $11.71 + $1.36, our arithmetic; assumes consensus includes the dilution |
| Annual dividend | $5.36 | 4 × $1.34 declared |
On 22x consensus 2027 EPS we get about $258. On 20x the pre-dilution figure, which adds back the $1.36 of deal dilution and assumes the consensus already includes it, we get about $261. Both bracket where the shares traded before publication, so we see the price as fair. The roughly 2% dividend yield is the main return we expect over 12 months.
The call
Neutral on JNJ for 12 months, no price target, moderate conviction. The medicines business is growing through Stelara's biosimilar erosion, and talc is close to settled. But MedTech needs fixing, reported EPS growth stays muted through 2027 and the valuation already reflects the pipeline. We will revisit once talc participation is confirmed and 2027 guidance is published.
This is the author's opinion, not investment advice. Figures are from Johnson & Johnson's Q3 2026 press release, schedules and call, and its July 2026 talc and guidance announcements; the valuation arithmetic is our own.
Discussion
Loading comments…